Global Information
회사소개 | 문의 | 위시리스트

분석 툴 : 암치료용 프로테인 키나아제 억제제

Protein Kinase Inhibitors in Oncology: Analytical Tool

리서치사 BioSeeker Group AB
발행일 2018년 12월 상품 코드 166080
페이지 정보 영문
US $ 4,450 ₩ 5,229,000 Desktop App plus Online Access to Updates (One Year) - Single User
US $ 8,900 ₩ 10,459,000 Desktop App plus Online Access to Updates (One Year) - Site License
US $ 13,350 ₩ 15,688,000 Desktop App plus Online Access to Updates (One Year) - Global License

분석 툴 : 암치료용 프로테인 키나아제 억제제 Protein Kinase Inhibitors in Oncology: Analytical Tool
발행일 : 2018년 12월 페이지 정보 : 영문

본 보고서는 종양 치료 분야에서 사업 개발, 사업이나 기업에 관한 정보 수집, 임상 개발 등에 종사하고 있으며, 주목도가 높고 빠르게 발전하고 있는 이 분야에서 우위를 유지하기 원하는 조직의 관계자에게 꼭 필요한 핸드북입니다. 달리 유례를 볼 수 없는 이 보고서는 프로테인 키나아제 억제제의 시판후 조사나 정보 수집에서 경쟁사에 대한 우위를 확보하고, 정확한 의사결정을 실시하여 실적을 확대시키는데 도움이 될 것으로 생각됩니다.

본 보고서는 프로테인 키나아제 억제제 개발 상황을 지속적으로 정밀 조사하고 최신 정보를 제공합니다.

  • 계약과 협력
  • 새로운 기술/의약품(특허, 조성, 각종 학회에서의 연구 발표 요지 등에서 얻을 수 있는 정보)
  • 자금 조달/조성/신규 주식 공개
  • 출원과 승인
  • 임상시험의 최신 동향과 결과
  • 새롭게 개시된 임상시험
  • 세계 각지에서 개최되고 있는 종양학 관련 12개 주요 학회 취재*
  • 분기 보고서와 연차 보고서

본 보고서를 활용해 이 분야의 매일의 동향을 거의 완전하게 파악할 수 있으며, 제품 개발 파이프라인의 종합적인 점검을 실시하거나 경쟁사를 평가할 수 있습니다. 또한 각종 요인에 입각한 종양 치료 분야의 비지니스 기회와 경쟁사를 특정하고, 우선순위를 설정하고, 과학적 평가를 이끌어낼 수 있습니다.

  • 최신 기술
  • 표적의 신규성
  • 최신의 연구 성과
  • 조기 단계 및 후기 단계의 파이프라인
  • 바이오마커/동반진단의 개발
  • 체결된 계약과 제휴
  • 세계의 주요 암관련 학회 취재
  • 병용요법의 선택사항
  • 임상시험 결과
  • 적응증의 선택과 적응 확대의 선택사항
  • 기존 약재 개발의 가능성

본 보고서는 현재 1,668 품목의 프로테인 키나아제 억제제 개발에 임하고 있는 508개사 이상의 기업과 제휴 기업을 망라한 것으로, 그 중 940 품목은 322 종류의 표적 암에 대응하는 제품으로서 적극적으로 개발이 진행되고 있습니다. 본 조사 보고서의 분석 툴로 얻을 수 있는 데이터와 분석은 클라이언트가 보존할 수 있으며, 데이터/그래프/표를 Excel/PDF 등 다양한 형식의 파일로 Export하고, 클라이언트가 독자적으로 모은 정보와 조합할 수도 있습니다.

시스템의 요구 사양

  • 브라우저 애플리케이션(Internet Explorer, FireFox, Chrome, Safari에 대응)
  • 인터넷 액세스
KSM 19.08.26

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

Kinase-targeted cancer therapies became really big with imatinib (Gleevec), a landmark drug that has vastly improved the outcomes of patients with chronic myelogenous leukemia. With the human genome encoding 538 protein kinases and many of these kinases being associated with human cancer initiation and progression, this field carries a lot of promise for more treatment successes in the future.

Protein Kinase Inhibitors in Oncology: Analytical Tool is the must have handbook for any business developer, BI/CI operative or clinical developer who needs to be on top of this hot and fast moving area of oncology. This unique product is truly the only tool of its kind and is designed to give you a competitive edge in your PKI drug surveillance and intelligence, allowing you to power your decision making and advance your own interests.

Keeping you "In the know"

Simply put, our mission is to fuel your knowledge of oncology, to make you the first to know about very early technologies and startups, emerging clinical trial results, drug approvals and the ever-changing competitive landscape. Protein Kinase Inhibitors in Oncology: Analytical Tool achieves this by continuously scanning development in PKI and reporting:

  • Deals & Collaborations
  • New technologies/drugs (emerging from patents, grants, abstracts (see Conference Coverage) etc.)
  • Funding/Grants/IPOs
  • Filings & Approvals
  • Latest Clinical Trial Development & Results
  • Newly launched clinical trials
  • Conference Coverage of the world's twelve leading meetings in oncology*
  • Quarterly & Annual Reporting

This puts you in control of most, if not all, day-to-day developments in your field while also benefiting from one of the most comprehensive commercial pipeline review & competitive assessment tools available on the market today! Identify, prioritize, and lead scientific assessment of oncology opportunities and competition by multiple factors such as:

  • Emerging Technologies
  • Target Novelty
  • Recent Funding
  • Early & Late Stage Pipeline
  • Biomarker/Companion Diagnostic Development (featured below)
  • Entered Deals & Alliances
  • Conference surveillance of world leading cancer meetings (featured below)
  • Combination Therapy Choices (featured below)
  • Outcome of Clinical Trials
  • Indication Selection & Expansion Choices
  • Drug Repositioning Opportunities

For 20 years we have supported better decision making across the oncology drug development industry. Your Protein Kinase Inhibitors in Oncology: Analytical Tool is based on two decades of proven methodology and transforms your computer's desktop into a high capacity workbench within your area of choice. Even before launching this tool you have already eliminated the hundreds of hours of work needed to discover, process and piece together the thousands of sources that our team of oncology dedicated and highly experienced contents specialists have done on your behalf.

Your Protein Kinase Inhibitors in Oncology: Analytical Tool covers more than 508 companies plus partners who are today developing 1668 PKI drugs where of 940 are in active development in cancer across 322 different targets. Any data and/or analysis from the Analytical Tool is yours to keep and data/graphs/tables can be easily exported into Excel/PDF and various graphic formats for mixing with your own proprietary information.

Let our expertise work for you

With a simple point and click interface you can navigate the environment of current development, drill down into specific areas such as ongoing combination trials, biomarker analysis, selected scientific abstracts etc. and generate drug profiles, drug target profiles and company profiles (including Business Development & Licensing contacts). Any analysis generated by you is packed with presentation-ready graphs and tables to use in your reports and presentations.

Your key to access development at the world-leading cancer meetings

The Protein Kinase Inhibitors in Oncology: Analytical Tool is continuously updated according to twelve of the world's most influential meetings in oncology (AACR, ASCO, ASGCT, ASH, CMIT, EHA, EORTC-NCI-AACR, ESMO, SITC and BIO (International, Europe and Asia). If you are not able to attend any of the conference(s) in person, this Analytical Tool ensures that you are not missing out on the important take home messages you need to know about.

Run combination therapy analysis like no other

The Protein Kinase Inhibitors in Oncology: Analytical Tool delivers comprehensive combination therapy analysis, allowing you to analyze combination therapies from multiple perspectives; from a single drug to virtually any cross section of oncology drugs of interest.

Unparalleled biomarker surveillance

We also provide an outstanding oncology clinical biomarker surveillance & analysis, highlighting clinical phenotyping and patient stratification in trials. This analysis is based on our monitoring of the presence and usage of more than 1,000 biomarkers across tens of thousands of cancer clinical trials.

Support and inspiration at your finger-tips

You also have access to a great selection of How-to Training Videos showing best practice approaches to aspects such as competitive pipeline analysis right through to many real world case examples put forward by other users of our Analytical Tools.

A tool to grow with and keep you informed

Unlike a static report which just represents a particular snapshot in time, all of the Analytical Tools come with one year of online access to twice-weekly updates in both contents and features, pipeline alerts and online support etc. You can choose to renew your access to these updates and support on a yearly basis or go over to our industry leading full service platform covering all oncology drug development, 1stOncology.

System Requirements

  • Browser Application (Supports: Internet Explorer, FireFox, Chrome and Safari))
  • Internet access
Back to Top
전화 문의